Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparative Analysis of Outcomes Among Rheumatoid Arthritis Patients Treated With Xeljanz Versus Biologic DMARDs Using a United States Healthcare Claims Database

NCT03964649 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03964649
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03964649 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparative Analysis of Outcomes Among Rheumatoid Arthritis Patients Treated With Xeljanz Versus Biologic DMARDs Using a United States Healthcare Claims Database
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
January 1, 2019
Completion date
April 6, 2020
Enrollment
7,308 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, rheumatoid